A Phase 3 interventional study of DTPa-HBV-IPV/Hib and DTPa-IPV/Hib vaccine in Haemophilus Influenzae Type b, Diphtheria and Tetanus, sponsored by GlaxoSmithKline. Completed at 3 sites in Singapore. Open to participants aged 11 Weeks to 17 Weeks, including healthy volunteers. Per ClinicalTrials.gov, last updated 2018-06-06.
Sponsored by GlaxoSmithKline · Phase 3, Interventional, and Prevention
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 13 studies testing diphtheria-tetanus-acellular pertussis-inactivated poliovirus-Haemophilus influenzae b conjugate-hepatitis B vaccine in Haemophilus Infections — none open to participants now, none under way, none of them phase 3. diphtheria-tetanus-acellular pertussis-inactivated poliovirus-Haemophilus influenzae b conjugate-hepatitis B vaccine · Haemophilus Infections.
Among the 13 studies testing diphtheria-tetanus-acellular pertussis-inactivated poliovirus-Haemophilus influenzae b conjugate-hepatitis B vaccine in Haemophilus Infections, this one is the 2nd largest by enrollment, is one of 2 that started in 2003, is one of 7 in phase 3, and was the 1st registered.
176 studies on the registry are indexed under Haemophilus Infections; 5 are open to participants now.
Browse Haemophilus Infections studies →None of the 13 studies testing diphtheria-tetanus-acellular pertussis-inactivated poliovirus-Haemophilus influenzae b conjugate-hepatitis B vaccine in Haemophilus Infections is open now. The open studies under Haemophilus Infections, anywhere →
No approval found in the FDA or EMA files read. How studies give it is on its page →
Of the 3 Haemophilus Infections studies recruiting now, none set no upper age limit and 3 stop at 75 or younger; 3 take children under 18; 3 take healthy volunteers.
This study: 11 Weeks to 17 Weeks · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
13 studies; the count open now beside each. This study's row is marked.
First in 1998; this study’s year is marked. 2 started in 2003.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 702 is above the median of 458 across 163 interventional studies indexed under Haemophilus Infections.
Median enrollment 494 across the 13 interventional studies. Of the 13 that completed or were terminated, 9 (69%) have results posted.
This tab as a report to print or save as PDF → With an account.
13 of 13 have an industry lead sponsor. The 2 most frequent:
GlaxoSmithKline is the lead sponsor of 3,652 studies on the registry; 118 are open to participants now.
Of its 267 completed or terminated interventional studies of FDA-regulated products, 241 (90%) have results posted.
82 studies in Haemophilus Infections by GlaxoSmithKline: none open now, none under way, none of them phase 3. Of 81 finished, 55 (68%) have results posted.
Among the 82 studies in Haemophilus Infections by GlaxoSmithKline, this one is the 21st largest by enrollment of the 80 interventional ones that give a count, is one of 7 that started in 2003, is one of 48 in phase 3, and was the 13th registered.
GlaxoSmithKline’s Haemophilus Infections studies by the year they started, since 1998.
None of the studies under way reaches primary completion within a year.
Among the 13 studies testing diphtheria-tetanus-acellular pertussis-inactivated poliovirus-Haemophilus influenzae b conjugate-hepatitis B vaccine in Haemophilus Infections, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among GlaxoSmithKline’s 82 in Haemophilus Infections:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
To assess the safety and reactogenicity of the DTPa-HBV-IPV/Hib vaccine and DTPa-IPV/Hib vaccine. This DTPa-IPV/Hib vaccine given at 3 and 4 months of age is co-administered with GSK Biologicals' rotavirus vaccine or Placebo. The Protocol Posting has been updated in order to comply with the FDA Amendment Act, Sep 2007.
Single group study. Subjects in GSK Biologicals' rotavirus study (Rota-028) in Singapore will be enrolled in this study.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion criteria
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Immunosuppression
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Healthy male or female subjects between and including 11 to 17 weeks of age, who were previously vaccinated with Rotarix™ in study 444563/028 (NCT00197210), additionally received 2 doses of Infanrix™-IPV/Hib vaccine (at 3 and 4 months of age), 2 doses of Rotarix™ vaccine (at 2 and 4 months of age) and one dose of Infanrix Hexa™ vaccine (at 5 months of age) as a primary vaccination course, followed by administration of a booster dose of Infanrix™-IPV/Hib vaccine (at 18 months of age). The Infanrix™-IPV/Hib and Infanrix Hexa™ vaccines were administered intramuscularly into the right antero-lateral thigh, while the Rotarix™ vaccine was given orally.
Biological: DTPa-HBV-IPV/Hib · Biological: DTPa-IPV/Hib vaccine
Drug page: Diphtheria-tetanus-acellular pertussis-inactivated poliovirus-Haemophilus influenzae b conjugate-hepatitis B vaccineStudies of Diphtheria-tetanus-acellular pertussis-inactivated poliovirus-Haemophilus influenzae b conjugate-hepatitis B vaccineDiphtheria-tetanus-acellular pertussis-inactivated poliovirus-Haemophilus influenzae b conjugate-hepatitis B vaccine pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.
1 intramuscular injection (3rd study vaccine dose)
Also known as: INFANRIX HEXA™
3 intramuscular injections (1st, 2nd and 4th vaccine dose)
Number of Subjects Reporting Any Solicited Local Symptoms
Assessed solicited local and general symptoms were pain, redness and swelling. Any = occurrence of the symptom regardless of intensity grade.
Time frame: During the 4-day (Days 0-3) post-vaccination period following each dose and across doses
Number of Subjects Reporting Any Solicited General Symptoms
Assessed solicited general symptoms were drowsiness, fever \[defined as axillary temperature equal to or above 37.5 degrees Celsius (°C)\], irritability and loss of appetite. Any = occurrence of the symptom regardless of intensity grade.
Time frame: During the 4-day (Days 0-3) post-vaccination period following each dose and across doses
Number of Subjects Reporting Any Unsolicited Adverse Events (AEs)
An unsolicited AE covers any untoward medical occurrence in a clinical investigation subject temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product and reported in addition to those solicited during the clinical study and any solicited symptom with onset outside the specified period of follow-up for solicited symptoms. Any was defined as the occurrence of any unsolicited AE regardless of intensity grade or relation to vaccination.
Time frame: During the 31-day (Days 0-30) post-vaccination period
Number of Subjects Reporting Any Large Swelling Reactions
A large swelling reaction was defined as swelling with a diameter greater than (\>) 50 millimeters (mm), noticeable diffuse swelling or noticeable increase of limb circumference.
Time frame: At Month 15, post-booster dose
Number of Subjects Reporting Any Serious Adverse Events (SAEs)
Serious adverse events (SAEs) assessed include medical occurrences that result in death, are life threatening, require hospitalization or prolongation of hospitalization or result in disability/incapacity.
Time frame: During the entire study period (from Month 0 up to Month 21)
| Milestone | Infanrix Hexa Group |
|---|---|
| Started | 702 |
| Completed | 676 |
| Not completed | 26 |
| Withdrew: Lost to follow-up(complete vacc. course) | 13 |
| Withdrew: Migrated/moved from study area | 1 |
| Withdrew: Lost to follow-up(incompl. vacc. course) | 4 |
| Withdrew: Withdrawal by subject | 8 |
Assessed solicited local and general symptoms were pain, redness and swelling. Any = occurrence of the symptom regardless of intensity grade.
| Participants | Infanrix Hexa Group |
|---|---|
| Any Pain, Dose 1 | 130 |
| Any Redness, Dose 1 | 120 |
| Any Swelling, Dose 1 | 89 |
| Any Pain, Dose 2 | 134 |
| Any Redness, Dose 2 | 137 |
| Any Swelling, Dose 2 | 100 |
| Any Pain, Dose 3 | 97 |
| Any Redness, Dose 3 | 126 |
| Any Swelling, Dose 3 | 100 |
| Any Pain, Booster dose | 166 |
| Any Redness, Booster dose | 148 |
| Any Swelling, Booster dose | 115 |
| Any Pain, Across doses | 301 |
| Any Redness, Across doses | 273 |
| Any Swelling, Across doses | 215 |
Assessed solicited general symptoms were drowsiness, fever \[defined as axillary temperature equal to or above 37.5 degrees Celsius (°C)\], irritability and loss of appetite. Any = occurrence of the symptom regardless of intensity grade.
| Participants | Infanrix Hexa Group |
|---|---|
| Any Drowsiness, Dose 1 | 165 |
| Any Temperature (Axillary) (°C), Dose 1 | 139 |
| Any Irritability, Dose 1 | 229 |
| Any Loss of appetite, Dose 1 | 173 |
| Any Drowsiness, Dose 2 | 140 |
| Any Temperature (Axillary) (°C), Dose 2 | 124 |
| Any Irritability, Dose 2 | 192 |
| Any Loss of appetite, Dose 2 | 155 |
| Any Drowsiness, Dose 3 | 106 |
| Any Temperature (Axillary) (°C), Dose 3 | 100 |
| Any Irritability, Dose 3 | 161 |
| Any Loss of appetite, Dose 3 | 106 |
| Any Drowsiness, Booster dose | 89 |
| Any Temperature (Axillary) (°C), Booster dose | 152 |
| Any Irritability, Booster dose | 163 |
| Any Loss of appetite, Booster dose | 118 |
| Any Drowsiness, Across doses | 290 |
| Any Temperature (Axillary) (°C), Across doses | 330 |
| Any Irritability, Across doses | 381 |
| Any Loss of appetite, Across doses | 324 |
An unsolicited AE covers any untoward medical occurrence in a clinical investigation subject temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product and reported in addition to those solicited during the clinical study and any solicited symptom with onset outside the specified period of follow-up for solicited symptoms. Any was defined as the occurrence of any unsolicited AE regardless of intensity grade or relation to vaccination.
| Participants | Infanrix Hexa Group |
|---|---|
| Number of Subjects Reporting Any Unsolicited Adverse Events (AEs) | 321 |
A large swelling reaction was defined as swelling with a diameter greater than (\>) 50 millimeters (mm), noticeable diffuse swelling or noticeable increase of limb circumference.
| Participants | Infanrix Hexa Group |
|---|---|
| Number of Subjects Reporting Any Large Swelling Reactions | 0 |
Serious adverse events (SAEs) assessed include medical occurrences that result in death, are life threatening, require hospitalization or prolongation of hospitalization or result in disability/incapacity.
| Participants | Infanrix Hexa Group |
|---|---|
| Number of Subjects Reporting Any Serious Adverse Events (SAEs) | 108 |
Collected over Solicited local/general symptoms: during the 4-day (Days 0-3) post-vaccination period; Unsolicited AE(s): during the 30-day (Days 0-29) post-vaccination period; SAE(s): during the entire study period (Month 0 to Month 21).. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Infanrix Hexa Group | 0/702 (0%) | 108/702 (15.4%) | 594/702 (84.6%) |
| Event | Infanrix Hexa Group |
|---|---|
| BronchiolitisInfections and infestations | 30/702 |
| Febrile convulsionNervous system disorders | 13/702 |
| GastroenteritisInfections and infestations | 11/702 |
| Upper respiratory tract infectionInfections and infestations | 11/702 |
| Gastritis viralInfections and infestations | 7/702 |
| Head injuryInjury, poisoning and procedural complications | 5/702 |
| AsthmaRespiratory, thoracic and mediastinal disorders | 5/702 |
| Urinary tract infectionInfections and infestations | 5/702 |
| Escherichia urinary tract infectionInfections and infestations | 4/702 |
| Gastroenteritis viralInfections and infestations | 4/702 |
| Event | Infanrix Hexa Group |
|---|---|
| IrritabilityGeneral disorders | 381/697 |
| Fever (Axillary) (°C)General disorders | 330/697 |
| Loss of appetiteGeneral disorders | 324/697 |
| PainGeneral disorders | 301/697 |
| DrowsinessGeneral disorders | 290/697 |
| RednessGeneral disorders | 273/697 |
| SwellingGeneral disorders | 215/697 |
| Upper respiratory tract infectionInfections and infestations | 125/702 |
| PyrexiaGeneral disorders | 46/702 |
| DiarrhoeaGastrointestinal disorders | 40/702 |
| Age, Continuous(Weeks) | Infanrix Hexa Group |
|---|---|
| Mean | 13.5 ± 0.99 |
| Sex: Female, Male(Participants) | Infanrix Hexa Group |
|---|---|
| Female | 349 |
| Male | 353 |
| Race/Ethnicity, Customized(Participants) | Infanrix Hexa Group |
|---|---|
| White/Caucasian | 1 |
| Japanese | 1 |
| Not specified | 27 |
| Chinese | 366 |
| Malay | 269 |
| Indian | 38 |
Plan to share: Yes — Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.
The record gives a start of Dec 2003, a primary completion of Feb 2007 and a completion of Feb 2007. It does not say whether these dates are actual or estimated.
Results were first posted in Feb 2017, 10 years after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in May 2018. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Diphtheria-tetanus-acellular pertussis-inactivated poliovirus-Haemophilus influenzae b conjugate-hepatitis B vaccine